• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

适用于沙库巴曲缬沙坦治疗的心力衰竭患者的健康相关生活质量。

Health-related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan.

机构信息

Department of Nursing Umeå University Umeå Sweden.

Department of Public Health and Clinical Medicine Umeå University Umeå Sweden.

出版信息

Nurs Open. 2019 Nov 19;7(2):556-562. doi: 10.1002/nop2.420. eCollection 2020 Mar.

DOI:10.1002/nop2.420
PMID:32089852
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7024611/
Abstract

AIM

To describe and compare self-reported health-related quality of life between younger and older patients with severe heart failure eligible for treatment with sacubitril-valsartan and to explore the association between health-related quality of life and age, NYHA classification, systolic blood pressure and NT-proBNP level.

DESIGN

Cross-sectional study.

METHODS

A total of 59 patients, eligible for treatment with sacubitril-valsartan were consecutively included and divided into a younger (≤75 years) and older group (>75 years). Health-related quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5-dimensions. Data were collected between June 2016 and January 2018. The STROBE checklist was used.

RESULTS

There were no differences in overall health-related quality of life between the age groups. The older patients reported lower scores in two domains measured with the Kansas City Cardiomyopathy Questionnaire, namely self-efficacy (67.0 22.1 vs. 78.8 19.7) and physical limitation (75.6 19.0 vs. 86.3 14.4). Higher NYHA class was independently associated with lower Kansas City Cardiomyopathy Questionnaire Overall Summary Score.

摘要

目的

描述和比较适合使用沙库巴曲缬沙坦治疗的年轻和老年重症心力衰竭患者的自我报告健康相关生活质量,并探讨健康相关生活质量与年龄、纽约心脏协会(NYHA)心功能分级、收缩压和 N 末端 B 型利钠肽前体(NT-proBNP)水平之间的关系。

设计

横断面研究。

方法

连续纳入 59 例适合使用沙库巴曲缬沙坦治疗的患者,并分为年轻(≤75 岁)组和老年(>75 岁)组。采用堪萨斯城心肌病问卷和欧洲五维健康量表评估健康相关生活质量。数据采集时间为 2016 年 6 月至 2018 年 1 月。采用 STROBE 清单。

结果

两组间总体健康相关生活质量无差异。老年组在两个用堪萨斯城心肌病问卷测量的领域报告的评分较低,即自我效能(67.0±22.1 比 78.8±19.7)和身体限制(75.6±19.0 比 86.3±14.4)。较高的 NYHA 心功能分级与堪萨斯城心肌病问卷总体综合评分较低独立相关。

相似文献

1
Health-related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan.适用于沙库巴曲缬沙坦治疗的心力衰竭患者的健康相关生活质量。
Nurs Open. 2019 Nov 19;7(2):556-562. doi: 10.1002/nop2.420. eCollection 2020 Mar.
2
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.沙库巴曲缬沙坦对比标准药物治疗对射血分数保留心力衰竭患者血浆 NT-proBNP 浓度和亚极量运动能力的影响:PARALLAX 随机临床试验。
JAMA. 2021 Nov 16;326(19):1919-1929. doi: 10.1001/jama.2021.18463.
3
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭患者健康状况的改善。
JACC Heart Fail. 2021 Jan;9(1):42-51. doi: 10.1016/j.jchf.2020.09.012. Epub 2020 Nov 11.
4
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.沙库巴曲缬沙坦治疗伴或不伴糖尿病的心力衰竭患者后的心脏逆重构。
JACC Heart Fail. 2021 Feb;9(2):137-145. doi: 10.1016/j.jchf.2020.09.014. Epub 2020 Dec 9.
5
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.血管紧张素-脑啡肽酶抑制剂在射血分数保留的心力衰竭中的应用。
N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.
6
Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience.慢性心力衰竭门诊患者和沙库巴曲缬沙坦治疗患者感知生活质量和功能能力的趋势:真实体验。
Minerva Cardiol Angiol. 2022 Oct;70(5):555-562. doi: 10.23736/S2724-5683.20.05494-8. Epub 2021 Apr 7.
7
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭患者的效果:一项随机临床试验。
JAMA Cardiol. 2022 Jan 1;7(1):17-25. doi: 10.1001/jamacardio.2021.4567.
8
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.沙库巴曲缬沙坦对心力衰竭患者身体活动和社会活动受限的影响:PARADIGM-HF 试验的二次分析。
JAMA Cardiol. 2018 Jun 1;3(6):498-505. doi: 10.1001/jamacardio.2018.0398.
9
Health-related quality of life outcomes in PARAGON-HF.PARAGON-HF研究中与健康相关的生活质量结局
Eur J Heart Fail. 2022 Dec;24(12):2264-2274. doi: 10.1002/ejhf.2738. Epub 2022 Dec 9.
10
Use of sacubitril/valsartan early after CABG.CABG 术后早期使用沙库巴曲缬沙坦。
Open Heart. 2024 Jan 18;11(1):e002492. doi: 10.1136/openhrt-2023-002492.

本文引用的文献

1
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.沙库巴曲缬沙坦对心力衰竭患者身体活动和社会活动受限的影响:PARADIGM-HF 试验的二次分析。
JAMA Cardiol. 2018 Jun 1;3(6):498-505. doi: 10.1001/jamacardio.2018.0398.
2
Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study.沙库巴曲缬沙坦在真实世界心力衰竭人群中的适用性:一项以社区为基础的单中心研究。
ESC Heart Fail. 2018 Apr;5(2):337-343. doi: 10.1002/ehf2.12251. Epub 2018 Jan 18.
3
Health-Related Quality of Life Outcomes in PARADIGM-HF.PARADIGM-HF 研究中的健康相关生活质量结局。
Circ Heart Fail. 2017 Aug;10(8). doi: 10.1161/CIRCHEARTFAILURE.116.003430.
4
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.2016年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南
Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1167. doi: 10.1016/j.rec.2016.11.005.
5
Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience.沙库巴曲缬沙坦在临床实践中应用的实际考量:当前证据与早期经验
Int J Cardiol. 2016 Nov 15;223:781-784. doi: 10.1016/j.ijcard.2016.08.323. Epub 2016 Aug 23.
6
What Is Known About the Benefits of Patient-Centered Care in Patients with Heart Failure.关于以患者为中心的护理对心力衰竭患者的益处已有哪些了解。
Curr Heart Fail Rep. 2015 Dec;12(6):350-9. doi: 10.1007/s11897-015-0272-6.
7
Predictors of hospitalization and quality of life in heart failure: A model of comorbidity, self-efficacy and self-care.心力衰竭住院和生活质量的预测因素:合并症、自我效能和自我护理模型。
Int J Nurs Stud. 2015 Nov;52(11):1714-22. doi: 10.1016/j.ijnurstu.2015.06.018. Epub 2015 Jul 17.
8
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
9
Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study.以患者为中心的综合慢性心力衰竭和姑息家庭护理的效果。PREFER:一项随机对照研究。
Eur J Heart Fail. 2014 Oct;16(10):1142-51. doi: 10.1002/ejhf.151. Epub 2014 Aug 27.
10
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).在血管紧张素受体脑啡肽酶抑制剂(ARNI)与血管紧张素转换酶抑制剂(ACEI)前瞻性比较以确定对心力衰竭试验(PARADIGM-HF)中全球死亡率和发病率影响的研究中患者的基线特征及治疗情况。
Eur J Heart Fail. 2014 Jul;16(7):817-25. doi: 10.1002/ejhf.115. Epub 2014 Jun 3.